Finance

Lists
Why is HUMA down 3.19%?
Dive Deeper
HUMA:NASDAQ
Humacyte Inc
$0.40
-3.19%
(-0.013) 1D
$0.40
+0.48% (+0.0019)
After hours
Closed: Nov 2, 4:00:02 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HUMA...
Open
$0.42
High
$0.43
Low
$0.38
Mkt. cap
110.92M
Avg. vol.
5.53M
Volume
0.00
52-wk high
$1.68
52-wk low
$0.34
EPS
-$0.49
Beta
2.44
Shares outstanding
277.80M
No. of employees
184
Open
$0.42
High
$0.43
Low
$0.38
Mkt. cap
110.92M
Avg. vol.
5.53M
Volume
0.00
52-wk high
$1.68
52-wk low
$0.34
EPS
-$0.49
Beta
2.44
Shares outstanding
277.80M
No. of employees
184
News stories
From web sources and news partners
About Humacyte Inc
CEOLaura Niklason
Employees184
FoundedJan 1, 2004
Headquarters-
SectorBiotechnology
Websitehumacyte.com
Analyst ratings
Based on 4 analysts giving stock ratings to HUMA in the past 3 months
Buy
Buy
2
Hold
2
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for HUMA in the last 3 months.
Highest
Current $0.40
$4.00 (+904.77%)
Average
$1.69 (+324.52%)
Lowest
$0.50 (+25.60%)
Analyst
Recommendation
Action
Price target
Projected
Date
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
$4.00
+904.8%
10/16/2026
Christopher Pasquale
Barclays
Hold
Initiated
$0.50
+25.6%
10/07/2026
Matt Miksic
Barclays
Hold
Maintained
$0.50
+25.6%
10/07/2026
Josh Jennings
TD Cowen
Buy
Maintained
$1.25
+214%
08/19/2026
Allison Bratzel
Piper Sandler
Hold
Maintained
$1.00
+151.2%
08/17/2026
Ryan Zimmerman
BTIG
Buy
Maintained
$2.00
+402.4%
07/28/2026
Bruce Jackson
Benchmark Co.
Buy
Maintained
$2.00
+402.4%
06/01/2026
Next call in 7 days
Tue, Nov 10, 8:00 AM
Fiscal period
Q3 2026
- / -$0.08
Revenue / Est. (USD)
- / 770.00K
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
753.00K
467.00K
495.00K
406.00K
Cost of goods sold
17.53M
23.69M
20.90M
19.38M
Cost of revenue
17.53M
23.69M
20.90M
19.38M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.61M
7.62M
7.83M
8.03M
Operating expense
7.61M
7.62M
7.83M
8.03M
Total operating expenses
25.14M
31.30M
28.73M
27.40M
Operating income
-24.39M
-30.84M
-28.24M
-27.00M
Other non operating income
4.01M
20.57M
8.52M
-5.16M
EBT including unusual items
-17.51M
-24.80M
-17.62M
-36.80M
EBT excluding unusual items
-22.40M
-12.85M
-21.65M
-34.08M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-17.51M
-24.80M
-17.62M
-36.80M
Net profit margin
-2,325.37%
-5,311.35%
-3,559.39%
-9,064.53%
Earnings per share
-0.11
-0.13
-0.09
-0.16
Interest and investment income
590.00K
503.00K
330.00K
388.00K
Interest expense
-2.61M
-3.09M
-2.27M
-2.32M
Net interest expenses
-2.02M
-2.59M
-1.94M
-1.93M
Depreciation and amortization charges
-
-
-
-
EBITDA
-22.52M
-29.05M
-26.44M
-25.21M
Gain or loss from assets sale
-
5.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps